Title: News Tomato– LegoChem speaks in the world's largest Anti-infection Conference.

Publication: News Tomato/ Kyung Mee Moon

Date: 01 October 2011

Summary

• After passing the technology evaluation for KOSDAQ IPO, LegoChem was invited to the world's largest anti-infection conference ICAAC to give a presentation on the accomplishments. 

• LegoChem announced their newly developed Oxazolidinone antibiotics showed superb efficacy and safety on treating a super bacteria known as “MRSA", so the company has filed an IND to Food and Drug Administration to conduct phase 1 experiment.                          

• LegoChem focuses on researching antibiotics, anticoagulants, oncology and advanced platform technology, or ADC (Antibody-Drug Conjugates). 

• One of the most important accomplishments of LegoChem is development of ADC technology, which combines targeting ability of antibody and medicinal efficacy of small molecule drugs.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).